Practising Law Institute (PLI) will be holding a seminar on Developments in Pharmaceutical and Biotech Patent Law 2015 on September 18, 2015 in San Francisco, CA and on October 2, 2015 in New York, NY. The San Francisco session will also be offered as a webcast. Topics to be covered at the seminar include:
• How IPRs relate to ANDA and biosimilar litigation;
• Preparing to face IPRs;
• Top pharmaceutical and biotech court decisions from 2014 and 2015;
• Biosimilars: The approval process, data exclusivity and patent litigation;
• Recent Supreme Court decisions and the Court's continued focus on patent law;
• Evolution of the lower courts' approach to indefiniteness and claim construction in view of recent Supreme Court decisions and what it means in pharmaceutical and biotech cases;
• Patentable subject matter under Section 101 in the aftermath of Myriad and Mayo;
• Update on USPTO Patentability Guidelines on patentable subject matter;
• Claim drafting, litigation and legislation in view of recent Section 101 case law;
• Ethical considerations impacting patent practice, including false declarations and data in patent applications, best mode violations after the AIA, advanced conflict waivers specific to IP matters; and
• Pre-pleading investigations, document retention, and the use of experts.
A program schedule and list of speakers for each of the locations can be found here.
The registration fee for the conference is $1,695. Those interested in registering for the conference can do so at the PLI website.
Comments